Slide 1: Cover letter to National Stock Exchange of India
Date: 17.05.2025 To National Stock Exchange of India Limited ‘Exchange Plaza’, Bandra-Kurla Complex Bandra (East), Mumbai 400051 Scrip Symbol: ACCENTMIC ISIN: INE0Q5D01013 Sub : Investor presentation for the Half year and Year ended 31st March 2025 Pursuant to the requirements of Regulation 30 of th
Slide 2: Investor Presentation 31 March 2025
accent bonding precision ACCENT MICROCELL \\-9i LIMITED a Investor Presentation 31° March 2025
Slide 3: Disclaimer
» DISCLAIMER This presentation and the accompanying slides (the “Presentation”), which have been prepared by Accent Microcell Limited (the “Company’), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any sec
Slide 4: Company Overview
COMPANY OVERVIEW Established in 2012 as a company, Accent embarked on its journey as a dedicated manufacturer and supplier of pharmaceutical excipients, driven by a strong commitment to technology and quality. Since then, Accent has steadily evolved into one of India’s fastest- growing companies in
Slide 5: Company Snapshot
COMPANY SNAPSHOT 15+ 75+ Product grades Countries Certified to operate 24 200+ Years Team Members of Operation since 2001 4 Brands Accel, Acrocell, Maccel and Vincel d accent | 4 VISION .\ I ly ~= - <Ox a ; \» As a_ global leader in pharmaceutical excipients, we are committed to sustainable growth,
Slide 6: Our Journey
OUR * Certified by FSSC-22000 + Started working on annual Incorporated as a oe and Habitencho Ni pale i Establishment of Commenced Company under the overseas (USA, Received a Exports Name “Accent Microcell EU, Australia, EXCIPACT Private Limited” Indonesia) Certification Making Our Mark Scaling Capa
Slide 7: Our Certificates
OUR CERTIFICATES Cerin 12400000098. Accent Microcell Limited soos ego rama (88 oF VR Gara Mar. Fr. Maro 400029 HALAL CERTIFICATE orn a a Certificate of Registration ACCENT MICROCELL LIMITED ‘Otc: 34, Shangila Arcade, Shyamal Cross Road, Quality Management system Maratea Sup f Ect ot oon Pris ke tere
Slide 8: Key Strengths
KEY STRENGTHS Global Market Expansion Strengthen international presence by entering new markets and deepening reach in existing geographies through Strategic partnerships and regulatory accreditations. Innovation-Led Product Development Forward-looking approach to business growth and decision- makin
Slide 9: Product portfolio: MCC, Silicified MCC, Magnesium Stearate
Microcrystalline Silicified MCC Spheres Cellulose (MCC) Microcrystalline Cellulose (SMCC) binding, and Enhanced binding, and * Multiple gradi 101 cS ‘ AACA Enhanced flow, binding, and 105, etc.) i ins compactibility * Applications: Binder, diluent, el) ‘ Grades: SMCC 50, 90, HD 90, 90 theology modif
Slide 10: Industries We Serve
: INDUSTRIES WE SERVE Pharmaceutical and Nutraceutical Food, Bakery & Dairy Companies Cosmeceuticals & Personal Care Welding Electrodes d accent | 9
Slide 11: Our Global Presence
OUR GLOBAL PRESENCE ¢ 17+ years of demonstrated experience in exports coupled with superior quality 14,152.22 Lakhs (53.49%) of the Company’s Revenue comes from exports. 12,305.47 Lakhs (46.51%) of the Company’s Revenue comes from domestic markets.
Slide 12: Global MCC industry growth
The global microcrystalline cellulose (MCC) industry is experiencing steady growth, with the market valued at around USD 1.4 billion in 2025 and projected to reach approximately USD 2.5 billion by 2032- 2035, reflecting a CAGR of about 7%. This growth is primarily driven by strong demand from the ph
Slide 13: Competitive Strengths
COMPETITIVE Innovation-Driven R&D Continuous investment in research and development to enhance product customization cise and reduce controllable costs. Proven Expertise in Process Scaling Diversified Market Presence Demonstrated capability in scaling and sustaining complex processes while consisten
Slide 14: Our Promoters
OUR PROMOTER Mr. Vasant Vadilal Patel Chairman He brings 21+ years of higher experience in the dyes, pharmaceuticals, and nutraceuticals industries. He has expertise in product development, marketing, and offshore product development strategies. Prior to founding Accent, he worked in industrial phar
Slide 15: Key Business Highlights
KEY BUSINESS HIGHLIGHTS Expanded & Diversified Product Portfolio Broadened offerings across multiple categories, catering to varied industry needs with innovative and high-performance materials. Robust Presence in Domestic & International Markets Strengthened market footprint in India while expandin
Slide 16: Manufacturing Facility
MANUFACTURING FACILITY Pe Pirana (Ahmedabad) - Unit | Key Highlights Product Flexibility & Customer-Centric Approach: Installed Capacity: 2,000 MTPA Efficiency & Quality Commitment: Capacity Utilisation: 100% « Multiple grade options backed by scalable capacity Area: 3,900.33 sq. mtrs. « Latest tech
Slide 17: Manufacturing Facility
MANUFACTURING FACILITY Pe Pirana (Ahmedabad) - Unit | Key Highlights Product Flexibility & Customer-Centric Approach: Installed Capacity: 2,000 MTPA Efficiency & Quality Commitment: Capacity Utilisation: 100% « Multiple grade options backed by scalable capacity Area: 3,900.33 sq. mtrs. « Latest tech
Slide 18: Investment Highlights: Third Facility Expansion
INVESTMENT HIGHLIGHTS Strategic Expansion: Establishing a third manufacturing facility at Nayka Kheda, Gujarat, to enhance production capacity and product diversification. Capacity Boost: Increases total installed capacity from 9,200 MTPA to 12,000 MTPA, addressing growing demand and enabling future
Slide 19: Order Forecast
ORDER FORECAST Strengthening Operational Stability oo Confirmed Orders Secured for the Next 3 Months: Secured pipeline of confirmed orders provides clarity on short-term business volume. Stable Workflow & Production Continuity A steady inflow of orders ensures consistent workload across departments,
Slide 20: Roadmap to Future Growth
ROADMAP T0 FUTURE \ GROWTH Targeted Customer Segments for Deeper. Diverse Segments Added Products Market Penetration Expanding Focus on Value Applications Across Pharmaceutical Companies Nutraceutical Companies Generic Drug Manufacturers Contract Manufacturing Organizations Exploring future potentia
Slide 21: Domestic vs Exports and Capacity Utilisation
Domestic 46.51% accent Exports 53.49 % UNIT 2 78.3% Our total existing installed capacity from the two facilities i.e. Unit-I| and Il is 9200 metric tonnes per annum
Slide 22: Profit & Loss Statement
PROFIT & LOSS STATEMENT (@ in Lakhs) , H2FY25 H1FY25 H2FY24 FY 24-25 FY 23-24 Particulars (Audited) (Reviewed) (Audited) (Audited) (Audited) Revenue from Operations 13,854.01 12,603.67 10% 13,863.06 0% 26,457.69 24,549.78 8% Other Income 343.53, 297.33 16% 188.11 83% 640.85 362.95 77% Total income 1
Slide 23: Balance Sheet
BALANCE SHEET (& in Lakhs) Particulars FY 2024-25 FY 2023-24 Equity Capital 2,104.30 2,104.30 Reserves 17,374.97 14,279.11 Borrowings 151.23, 1,279.09 Other Liabiities 3,206.94 2,821.47 Total Liabilities 22,837.44 20,483.97 Fixed Assets 4,799.13 2,903.76 LOANS & ADVANCES 1,584.39 8,152.05 CWIP. 1,27
Slide 24: Financial Analysis
FINANCIAL ANALYSIS Revenue from Operations increased by 8% YoY to 326,457.69 Cr, sho steady business growth. 4831.76 3306.29 apie 26457.69 ppl 24549.78 : 12% 7 ; e 2 e 2 e FY24 FY25 FY24 FY25. FY24 FY25, (Audited) (audited) (Audited) (Audited) (Audited) (Audited) REVENUE PAT EBITDA (2 IN LAKHS) (IN
Slide 25: Finportal investor relations contact
<> FINPORTAL & abhishek Bhutra [Himanshu Jain +91 80006 85556, +91 89051 81853 & ir@finportalin.com